Tag Archive for: Cybin

Single Dose Of Next-Gen Psilocybin Shows Significant Reduction In Depression, 20% No Longer Needing Treatment

Single Dose Of Next-Gen Psilocybin Shows Significant Reduction In Depression, 20% No Longer Needing Treatment

The interim results show remarkable and rapid reduction in depression symptoms compared to traditional antidepressants three weeks after a single dose of next-generation psilocybin.
Math over Myth

Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3

,
Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Math over Myth

Math Over Myth: Weekly Psychedelic Stocks News Roundup

,
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
Cybin Entheon DMT Clinical TrialSutterstock

The Real Reason Cybin Bought Entheon’s DMT Clinical Trial

, ,
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

, ,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!

Psychedelic Business Spotlight – June 10

,
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and more!
5 Next-Generation Psychedelics Entering Clinical Trials This YearShutterstock

5 Next-Generation Psychedelics Entering Clinical Trials This Year

,
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.
Why Wednesday Will Be Biggest Day for Psychedelic Investors of 2022Shutterstock

Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors

,
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Shutterstock

Elon Musk Excites Psychedelic Industry CEOs with This Tweet

,
This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.